Medication Type | Patients (n) | Baseline | Adherent Members at the End of the Study (%)* | Change (End of Study − Baseline)† | |
---|---|---|---|---|---|
MPR (%) | Adherent Members (%)* | ||||
Diabetes (only) | |||||
Diabetes-specific‡ | |||||
Non-PCIP | 205 | 79.01 | 26.07 | 27.94 | +1.87 |
PCIP | 63 | 69.70 | 18.52 | 31.76 | +13.24 |
Lipid-controlling§ | |||||
Non-PCIP | 129 | 76.67 | 16.63 | 13.24 | −3.39 |
PCIP | 40 | 65.32 | 11.11 | 16.47 | +5.36 |
Hypertension (only) | |||||
Hypertension-specific† | |||||
Non-PCIP | 2652 | 79.37 | 33.75 | 37.88 | +4.13 |
PCIP | 735 | 77.61 | 32.89 | 37.25 | +4.36 |
Lipid-controlling§ | |||||
Non-PCIP | 1198 | 77.63 | 14.59 | 17.05 | +2.46 |
PCIP | 295 | 76.47 | 12.62 | 13.51 | +0.89 |
Comorbid diabetes and hypertension | |||||
Diabetes-specific‡ | |||||
Non-PCIP | 1322 | 79.67 | 37.37 | 37.87 | +0.50 |
PCIP | 357 | 76.63 | 36.04 | 37.10 | +1.06 |
Hypertension-specific‖ | |||||
Non-PCIP | 1533 | 79.52 | 44.44 | 47.76 | +3.32 |
PCIP | 390 | 77.39 | 40.57 | 41.94 | +1.37 |
Lipid-controlling§ | |||||
Non-PCIP | 1045 | 78.55 | 29.25 | 31.29 | +2.04 |
PCIP | 250 | 75.46 | 24.34 | 28.23 | +3.89 |
↵* The proportion of members with a medication possession ratio (MPR) ≥80%.
↵† Change in the proportion of members with an MPR ≥80% from baseline (2008) to the end of the study (2011).
↵‡ Diabetes therapeutic drug classes include biguanides, sulfonylureas, thiazolidinediones, insulins, and dipeptidyl peptidase IV inhibitors.
↵§ Lipid-controlling therapeutic drug classes include HMG-CoA reductase inhibitors and fibric acid derivatives.
↵‖ Hypertension therapeutic drug classes include angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, β-adrenergic blocking agents, calcium channel blocking agents (dihydropyridines), phosphodiesterase inhibitors, thiazide diruetics.
PCIP, Primary Care Information Project.